Eurotimes Articles

  • 04/02/2015 - 11:13 THERAPYFOR DME April, 2015, Retina The top three anti-VEGF agents – aflibercept (Eylea, Regeneron), bevacizumab (Avastin, Genentech/Novartis) and ranibizumab (Lucentis, Genentech/Novartis) – all appear to provide substantial clinical benefit for patients with diabetic macular oedema (DME), with aflibercept providing the greatest visual improvements.
  • 04/02/2015 - 10:40 TARGETED APPROACH April, 2015, Retina Early diagnosis, referral to a uveitis specialist and therapeutic aggressiveness employing a ‘stepladder’ approach that is both steroid-sparing and individually tailored offers the best approach to successfully treating uveitis.
  • 04/01/2015 - 14:53 REGENERATIVE MEDICINE April, 2015, Retina Photoreceptors and retinal pigment epithelial (RPE) cells are key candidates for transplantation therapy of retinal disease
  • 04/01/2015 - 10:01 INTRAVITREAL INJECTIONS April, 2015, Retina, Headlines A novel device shortlisted for the EURETINA Innovation Awards 2014 may provide a simple, easy-to-use solution to the problem of making intravitreal injections safer and more consistent
  • 03/03/2015 - 15:03 RISK PREDICTION ALGORITHM Mar, 2015, Retina, Headlines More cost-effective screening programmes are urgently needed to deal with the expected increase in diabetes...
  • 03/03/2015 - 14:42 OPHTHALMOLOGICA Mar, 2015, Retina Highlights from the peer-reviewed journal of EURETINA.
  • 03/03/2015 - 13:01 ABSOLUTE PRECISION Mar, 2015, Retina, Top Story A device designed to provide robotic assistance with micrometre precision in vitreoretinal surgery should enable surgeons to improve the reproducibility and speed of existing procedures and to develop treatments for diseases that have no adequate treatment.
  • 03/03/2015 - 11:19 CNV DETECTION Mar, 2015, Retina A home monitoring device could prove a useful ally in detecting the development of choroidal neovascularisation (CNV) at an earlier stage than current standard of care approaches.
  • 03/03/2015 - 10:50 INTRAVITREAL IMPLANT Mar, 2015, Retina Results of two studies indicate that the dexamethasone intravitreal implant, Ozurdex® (Allergan), can bring about significant and sustained improvements in vision in patients with diabetic macular oedema (DME), with generally only transient increases in intraocular pressure (IOP), but with a high incidence of cataract in phakic patients
  • 01/29/2015 - 12:22 OPHTHALMOLOGICA Feb, 2015, Retina Highlights from the December issue of Ophthyalmologica

Popular Items